



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



Elvitegravir-d₆ Item No. 28523

Formal Name: 6-[(3-chloro-2-fluorophenyl)methyl]-1,4-dihydro-1-[(1S)-1-(hydroxymethyl)-2-methylpropyl]-7-methoxy-4-oxo-3-quinolinecarboxylic acid-d₆

MF: C₂₃H₁₇CID₆FNO₅

FW: 453.9

Chemical Purity: ≥98% (Elvitegravir)


Deuterium

Incorporation: ≥99% deuterated forms (d₁-d₆); ≤1% d₀

Supplied as: A solid

Storage: -20°C

Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Elvitegravir-d₆ is intended for use as an internal standard for the quantification of elvitegravir (Item No. 17798) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated *versus* unlabeled).

Elvitegravir-d₆ is supplied as a solid. A stock solution may be made by dissolving the elvitegravir-d₆ in the solvent of choice, which should be purged with an inert gas. Elvitegravir-d₆ is slightly soluble in methanol and DMSO.

Description

Elvitegravir is a quinolone antibiotic that inhibits HIV-1 integrase (IC₅₀ = 7.2 nM).¹ It has antiviral activity against laboratory strains and clinical isolates of HIV-1 (EC₅₀s = 0.1-1.26 nM) in MAGI cells and HIV-2 (EC₅₀s = 0.3-0.9) in peripheral blood mononuclear cells (PBMCs).^{1,2} Formulations containing elvitegravir have been used in the treatment of HIV infections.

References

1. Sato, M., Motomura, T., Aramaki, H., *et al.* Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. *J. Med. Chem.* **49**(5), 1506-1508 (2006).
2. Roquebert, B., Damond, F., Collin, G., *et al.* HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir *in vitro*. *J. Antimicrob. Chemother.* **62**(5), 914-920 (2008).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/11/2019

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM